Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 2.1x - 2.3x | 2.2x |
| Selected Fwd Ps Multiple | 1.6x - 1.7x | 1.6x |
| Fair Value | €0.57 - €0.63 | €0.60 |
| Upside | 39.1% - 53.8% | 46.4% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Genscript Biotech Corporation | - | OTCPK:GNNS.F |
| Quanterix Corporation | - | NasdaqGM:QTRX |
| Standard BioTools Inc. | - | NasdaqGS:LAB |
| BioLife Solutions, Inc. | - | NasdaqCM:BLFS |
| Adaptive Biotechnologies Corporation | - | NasdaqGS:ADPT |
| ImmunoPrecise Antibodies Ltd. | - | DB:TQB |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| GNNS.F | QTRX | LAB | BLFS | ADPT | TQB | |||
| OTCPK:GNNS.F | NasdaqGM:QTRX | NasdaqGS:LAB | NasdaqCM:BLFS | NasdaqGS:ADPT | DB:TQB | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 16.8% | 19.4% | 8.3% | 24.6% | 16.0% | 17.5% | ||
| 3Y CAGR | 6.6% | 7.5% | 10.1% | -11.6% | 5.1% | 11.0% | ||
| Latest Twelve Months | 6.1% | 7.7% | 33.9% | 34.8% | 8.6% | 1.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -41.7% | -48.4% | -82.5% | -46.6% | -121.1% | -85.0% | ||
| Prior Fiscal Year | 75.4% | -23.2% | -70.2% | -24.3% | -132.3% | -128.5% | ||
| Latest Fiscal Year | -11.3% | -28.0% | -106.0% | -13.8% | -89.1% | -110.8% | ||
| Latest Twelve Months | -11.3% | -35.3% | -78.2% | -9.8% | -74.8% | -194.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 49.1x | 0.7x | -1.3x | -2148.5x | -11.7x | -2.8x | ||
| Price / LTM Sales | 5.6x | 1.4x | 2.2x | 12.1x | 7.3x | 1.5x | ||
| LTM P/E Ratio | -49.6x | -4.0x | -2.8x | -122.5x | -9.8x | -0.7x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 1.4x | 5.6x | 12.1x | |||||
| Historical LTM P/S Ratio | 2.0x | 4.3x | 13.4x | |||||
| Selected Price / Sales Multiple | 2.1x | 2.2x | 2.3x | |||||
| (x) LTM Sales | 24 | 24 | 24 | |||||
| (=) Equity Value | 50 | 53 | 55 | |||||
| (/) Shares Outstanding | 53.4 | 53.4 | 53.4 | |||||
| Implied Value Range | 0.94 | 0.99 | 1.04 | |||||
| FX Rate: CAD/EUR | 1.6 | 1.6 | 1.6 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.60 | 0.63 | 0.66 | 0.41 | ||||
| Upside / (Downside) | 46.6% | 54.3% | 62.0% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | GNNS.F | QTRX | LAB | BLFS | ADPT | TQB | |
| Value of Common Equity | 3,779 | 188 | 350 | 1,036 | 1,357 | 34 | |
| (/) Shares Outstanding | 2,788.7 | 38.8 | 379.8 | 47.6 | 151.9 | 53.4 | |
| Implied Stock Price | 1.36 | 4.85 | 0.92 | 21.78 | 8.93 | 0.64 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.56 | |
| Implied Stock Price (Trading Cur) | 1.36 | 4.85 | 0.92 | 21.78 | 8.93 | 0.41 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.56 | |